ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2530

Sustained Improvements In Health-Related Quality Of Life In Patients With Systemic Lupus Erythematosus following Epratuzumab Treament: Results from a Phase IIb Trial and Its Open-Label Extension

Vibeke Strand1, Joan T. Merrill2, Enkeleida Nikaï3, Brian Kilgallen4, Antoine Regnault5 and Caroline Gordon6, 1Stanford University, Palo Alto, CA, 2Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3UCB Pharma, Brussels, Belgium, 4UCB Pharma, Raleigh, NC, 5Mapi HEOR & Strategic Market Access, Lyon, France, 6Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: quality of life, systemic lupus erythematosus (SLE) and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus-Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Epratuzumab is a monoclonal antibody targeting CD22. Improvements in health-related quality of life (HRQoL) with epratuzumab in patients with systemic lupus erythematosus (SLE) have been reported in the ALLEVIATE trials from week 12 and sustained to 4 years.1,2 In the EMBLEM™ study (dose-ranging phase IIb randomized controlled trial [RCT] in SLE), epratuzumab treatment resulted in clinically relevant improvements in SLE disease activity.3  We report HRQoL data from EMBLEMTM and its open-label extension (OLE) (NCT00660881).

Methods:

In EMBLEMTM patients with moderate-to-severely active SLE (≥1 BILAG 2004 A or ≥2 Bs) were randomized to 1 of 6 intravenous regimens over 12 weeks added to standard of care (SOC): placebo (PBO) or cumulative dose (cd) epratuzumab (200, 800, 2400 or 3600 mg in equal divided doses using 2 every other week [EOW] infusions or 2400 mg cd as 600 mg every week [QW]). Patients from any EMBLEMTM arm completing 12 weeks blinded treatment and those who discontinued due to lack of efficacy but completed ≥8 weeks were eligible to enter the OLE where all patients received 1200mg epratuzumab at weeks 0 and 2 of repeating 12-week cycles. Short Form-36 (SF-36) Version 2.0 was used to assess HRQoL. Data are reported to the end of EMBLEMTM and to weeks 48 and 108 of the OLE (week 108 is last time-point when ≥ 50% of patients reported SF-36 data). Mean changes and % pts reporting improvements ≥ minimum clinically important differences (MCID) (Increases from baseline ≥5.0-points in domain and ≥2.5-points in physical and mental component scores [PCS and MCS]) are presented.  Observed case analyses are presented for the OLE.

Results:

In EMBLEMTM mean SF-36 PCS, MCS and domain scores across epratuzumab and placebo groups (both receiving background SOC) generally increased over time from baseline through week 12, with greater increases in the PBO group. Longer treatment with epratuzumab during OLE resulted in clinically meaningful changes in HRQoL vs EMBLEM baseline (Table).  At week 108 in the OLE 70.8% and 59.3% of patients reported improvements ≥ MCID in PCS and MCS scores.

Conclusion:

In the 12 week EMBLEMTM study treatment period no differences in improvements in HRQoL were observed with epratuzumab, which may be attributed to short term treatment, small sample sizes and active background (SOC) therapy.  Nonetheless, over a greater length of time sustained improvements were observed in the EMBLEMTM OLE, which are consistent with those in the ALLEVIATE RCTs.1,2

References:

1. Strand V. et al. ACR 2008; 2. Strand V. et al. Rheumatology in Press 3. Wallace DJ. et al. Ann Rheum Dis, Online First 12 January 2013. DOI: 10.1136/annrheumdis-2012-202760.

 

 


Disclosure:

V. Strand,

Abbott Immunology Pharmaceuticals, Amgen Inc, AstraZeneca, Biogen Idec, Canfite Pharma, Centocor Inc, Cypress Biosciences Inc, Euro-Diagnostica Inc, Fibrogen, Forest Laboratories, Genentech, Human Genome Sciences Inc, Incyte, Novartis Pharmaceuticals Corp,

5;

J. T. Merrill,

UCB Pharma,

5;

E. Nikaï,

UCB Pharma,

3;

B. Kilgallen,

UCB Pharma,

1,

UCB Pharma,

3;

A. Regnault,

UCB Pharma,

5;

C. Gordon,

GSK, MedImmune, Merck Serono, Parexel and UCB Pharma,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sustained-improvements-in-health-related-quality-of-life-in-patients-with-systemic-lupus-erythematosus-following-epratuzumab-treament-results-from-a-phase-iib-trial-and-its-open-l/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology